synthena.com Report : Visit Site

Technical data of the synthena.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host synthena.com. Currently, hosted in United Kingdom and its service provider is Cyber Host Pro Ltd .

the related websites

blackchat.co.uk fragilex.org.uk mr-foggs.com edfenergy.wesupply.net whatoildoineed.com mcclure-solicitors.co.uk firstforfife.co.uk zzps.debt-view.co.uk monmouthrc.org.uk gnomereserve.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called LiteSpeed containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

you are using an outdated browser. please upgrade your browser to improve your experience. about us leadership science products & pipeline contact about us leadership science products & pipeline news contact -- oligonucleotide based therapeutics treatment of genetic neuromuscular diseases by using its tricyclo-dna molecular technology about us synthena’s mission is to develop first in class drugs in the field of myopathy with a focus on the duchenne muscular dystrophy disease, based on its proprietary tricyclo-dna technology. its proprietary tricyclo-dna technology offers broad advantages over state of the art oligonucleotide chemistries for new rna intervention strategies like splice switching, and other antisense approaches. its most advanced preclinical drug development program focuses on duchenne muscular dystrophy, a genetic disorder which affects 1 in 3,500 boys and which leads to death in early adulthood. modulation of rna for therapeutic purposes holds the promise of opening up entirely new concepts for pharmaceutical intervention, however, current oligonucleotide chemistries to modulate rna do not meet the requirements for efficient delivery, pharmacokinetics and tolerability. leadership management team directors & founders management team bertranddamour chief executive officer mr. damour has been a biotech executive for more than 15 years. most recently he was chief executive officer at oncoethix a swiss oncology company sold to merck & co. before that mr. damour was chief executive officer of mind nrg a swiss company in the field of major cns pathologies sold to minerva neurosciences. prior to this, mr. damour was executive vice president and chief financial officer at egalet, a danish specialty pharmaceuticals company, now listed on the nasdaq. previously, mr. damour more was president and chief executive officer at geneprot, a us biotechnology company in the field of proteomics and genomics. before joining the biotech industry, mr. damour was an investment banker holding senior positions at bankers trust in new york and at deutsche bank, rabobank and jp morgan in london. mr. damour received his m.b.a. from the kellogg school of management at northwestern university, a master of engineering degree from the institut des sciences de la matiere et du rayonnement (ismra) in france, and a master in accounting and business administration degree from the institut d’aministration des entreprises (iae) in france. less branislav dugovic phd, chief technology officer studied chemistry at the slovak technical university since 2005. after performing post-doctoral work at the freie universität berlin he moved to university of bern in 2009, where he further developed and expanded the bicyclo- and tricyclo-dna molecular platforms. he joined synthena in 2012. adrian häberli phd, head quality control studied chemistry at the university of bern and graduated 2001 in the subject of oligonucleotide chemistry. following his postdoctoral studies in canada he held positions at interlabor and zlb behring. in 2005 he became head of the laboratory unit pharmacopoeia and scientific expert for forensic chemistry at the swiss medicines control agency swissmedic. directors & founders bertrand damour chairman of the board mr. damour has been a biotech executive for more than 15 years. most recently he was chief executive officer at oncoethix a swiss oncology company sold to merck & co. before that mr. damour was chief executive officer of mind nrg a swiss company in the field of major cns pathologies sold to minerva neurosciences. prior to this, mr. damour was executive vice president and chief financial officer at egalet, a danish specialty pharmaceuticals company, now listed on the nasdaq. previously, mr. damour more was president and chief executive officer at geneprot, a us biotechnology company in the field of proteomics and genomics. before joining the biotech industry, mr. damour was an investment banker holding senior positions at bankers trust in new york and at deutsche bank, rabobank and jp morgan in london. mr. damour received his m.b.a. from the kellogg school of management at northwestern university, a master of engineering degree from the institut des sciences de la matiere et du rayonnement (ismra) in france, and a master in accounting and business administration degree from the institut d’aministration des entreprises (iae) in france. less luc pettavino is directing the association monégasque contre les myopathies (amm). amm is heavily involved in supporting research towards cures for duchenne muscular dystrophy by financing and coordinating the international initiative ice (international collaborative effort) and the monaco round tables since 2003. prior to this position, luc pettavino was ceo and shareholder of the monaco yacht show. he created and organizes the biennal charity auction only watch. luis garcia phd luis garcia received his phd in 1989 at the university paris 7 (diderot) in the laboratory of michel fardeau (inserm u153/ua614 cnrs) on the role of the l-type ca 2+ channel in excitation-contraction coupling in skeletal muscle. after a post-doctoral experience (1989-1990) at the rockefeller university in the laboratory of prof. gerald m. edelman, he was appointed by the cnrs (1991) as a permanent researcher. in 1995, luis garcia integrated the inserm unit «neuroplasticity and therapeutics», more headed by marc peschanski (inserm u421) to explore raising fields such as cell or gene therapy. in 1997, he joined olivier danos at the genethon/umr8115 cnrs laboratory to initiate its transformation into a research centre on gene therapy, and later on in 2007, luis garcia moved my team to the university pierre & marie curie (inserm u974/cnrs umr7215) with the aim of developing therapeutic strategies based on mrna repair. in 2012, he was invited to join the new faculty of medicine of the university of versailles st-quentin to create an associated international laboratory uvsq-csm in monaco (lia-bahn - 2013) and a joint research laboratory uvsq-inserm in versailles (u1179 - 2015), both committed to investigating novel therapeutic approaches for neuromuscular disabilities in relationship with the university hospitals of “paris-ile-de-france ouest”. less science antisense technology is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the modulation of rna. its proprietary tricyclo-dna technology platform offers broad advantages over state of the art oligonucleotide chemistries for new rna intervention strategies like splice switching, and other antisense approaches. its most advanced preclinical drug development program focuses on duchenne muscular dystrophy, a genetic disorder which affects 1/3,500 boys and which leads to death in early adulthood. tricyclo-dna technology much as lna, tricyclo(tc)-dna has been designed as a conformationally constrained oligonucleotide analogue. chemically, tc-dna deviates from natural dna by three additional c-atoms between c(5’) and c(3’). these chemical modifications change the properties of natural oligodeoxynucleotides in the following way: increased rna affinity by 2 – 4°c / modification increased hydrophobicity increased stability towards nucleolytic degradation for both, phosphate or thiophosphate internucleoside linkages inability to elicit rnaseh activity tc-oligonucleotides are manufactured in the same way as natural or lna- oligonucleotides via solid phase phosphoramidite chemistry. unlike lna, fully modified tc-oligonucleotides in the lenght range of 11-25 nucleotides can easily be prepared and produce potent antisense effects. due to their properties tc-oligonucleotides are particularly suited for biological and therapeutic applications where high target affinity and biostability is required and where the mechanism of action does not rely on rnaseh activity. muscular

URL analysis for synthena.com

http://www.synthena.com/#top
http://www.synthena.com/#about
http://www.synthena.com/#pipeline
http://www.synthena.com/#contact
http://www.synthena.com/#leadership
http://www.synthena.com/#science

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: SYNTHENA.COM
Registry Domain ID: 1703969599_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.udag.net
Registrar URL: http://www.united-domains.de
Updated Date: 2018-02-26T08:22:59Z
Creation Date: 2012-02-25T08:50:23Z
Registry Expiry Date: 2019-02-25T08:50:23Z
Registrar: United-Domains AG
Registrar IANA ID: 1408
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +49.8151368670
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS.UDAG.DE
Name Server: NS.UDAG.NET
Name Server: NS.UDAG.ORG
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-03-22T17:21:24Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR United-Domains AG

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =synthena.com

  PORT 43

  TYPE domain

DOMAIN

  NAME synthena.com

  CHANGED 2018-02-26

  CREATED 2012-02-25

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS.UDAG.DE 185.61.8.10

  NS.UDAG.NET 89.31.141.10

  NS.UDAG.ORG 185.61.8.11

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .